Patents by Inventor Lloyd B. Jeffs
Lloyd B. Jeffs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240035030Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: June 7, 2023Publication date: February 1, 2024Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Patent number: 11718852Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: March 16, 2021Date of Patent: August 8, 2023Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Patent number: 11318098Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: GrantFiled: May 25, 2021Date of Patent: May 3, 2022Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Patent number: 11298320Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: GrantFiled: May 25, 2021Date of Patent: April 12, 2022Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Publication number: 20210275454Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: May 25, 2021Publication date: September 9, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Publication number: 20210275455Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: May 25, 2021Publication date: September 9, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Publication number: 20210267891Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: March 16, 2021Publication date: September 2, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Publication number: 20210207140Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: March 16, 2021Publication date: July 8, 2021Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Publication number: 20200268664Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: September 19, 2019Publication date: August 27, 2020Inventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Publication number: 20190167586Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: July 13, 2018Publication date: June 6, 2019Inventors: Ian MacLachlan, Lloyd B. Jeffs, Lorne R. Palmer, Cory Giesbrecht
-
Publication number: 20190032051Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: February 8, 2018Publication date: January 31, 2019Inventors: ED YAWORSKI, LLOYD B. JEFFS, LORNE R. PALMER
-
Publication number: 20170260523Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: November 2, 2016Publication date: September 14, 2017Inventors: ED YAWORSKI, LLOYD B. JEFFS, LORNE R. PALMER
-
Patent number: 9518272Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: May 12, 2016Date of Patent: December 13, 2016Assignee: PROTIVA BIOTHERAPEUTICS, INC.Inventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Publication number: 20160251681Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: May 12, 2016Publication date: September 1, 2016Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: ED YAWORSKI, LLOYD B. JEFFS, LORNE R. PALMER
-
Patent number: 9404127Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: March 9, 2015Date of Patent: August 2, 2016Assignee: PROTIVA BIOTHERAPEUTICS, INC.Inventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Publication number: 20160032320Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: March 9, 2015Publication date: February 4, 2016Inventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Patent number: 9006417Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: June 30, 2011Date of Patent: April 14, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
-
Patent number: 9005654Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. A therapeutic agent, such as nucleic acid, is included in one of the buffer solution or the lipid solution. Upon mixing a liposome encapsulating the therapeutic product is substantially instantaneously formed. Thereafter the liposome solution formed is immediately diluted with buffer solution to enhance homogeneity and maintain small particle size.Type: GrantFiled: July 27, 2006Date of Patent: April 14, 2015Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lloyd B. Jeffs, Edward Yaworski, Kieu Lam
-
Publication number: 20140161894Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer (e.g., Eg5, EGFR or XIAP) and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR or XIAP gene expression.Type: ApplicationFiled: October 30, 2013Publication date: June 12, 2014Applicant: Alnylam Pharmaceuticals, Inc.Inventors: Ian MacLachlan, Adam Judge, Vandana Sood, James Heyes, Lloyd B. Jeffs, Lorne Palmer
-
Patent number: 8598333Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer (e.g., Eg5, EGFR or XIAP) and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR or XIAP gene expression.Type: GrantFiled: May 29, 2007Date of Patent: December 3, 2013Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Ian MacLachlan, Adam Judge, Vandana Sood, James Heyes, Lloyd B. Jeffs, Lorne Palmer